The FDA has accepted the resubmission of the biologics license application (BLA) for ONS-5010 (bevacizumab-vikg) for the ...

PharmAbcine's pipeline is spearheaded by olinvacimab, an antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2; also known as KDR). The VEGF/VEGFR-2 pathways are central to ...

The researchers show that ephrin-B2 regulates the proper spatial activation of VEGFR-2 endocytosis and signaling at the tip cell filopodia. In vitro, endothelial cells from Efnb2-knockout and ...

VEGFR-2 specific immune response in GBM therapy warrant further study. "The completion of this Phase 2a study is a significant milestone for Vaximm AG, as it provides strong evidence that VXM01 ...

The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response in GBM therapy warrant further study.